Skip to main content
Baxdrostat (CIN-107) CAS#: 1428652-17-8
IdentificationPhysical DataSpectraRoute of Synthesis (ROS)Safety and HazardsOther Data

Identification

Product NameBaxdrostat (CIN-107)IUPAC NameN-propanamideMolecular StructureCAS Registry Number 1428652-17-8SynonymsBaxdrostatBaxdrostat NF3P9Z8J5Y1428652-17-8UNII-NF3P9Z8J5Y(+)-(R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamideN-((8R)-5,6,7,8-Tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)propanamidePropanamide, N-((8R)-5,6,7,8-tetrahydro-4-(1,2,3,4-tetrahydro-1-methyl-2-oxo-6-quinolinyl)-8-isoquinolinyl)-CIN107CHEMBL4113975SCHEMBL14799753GTPL12362CIN-107BDBM233806GLXC-26998MS-25786HY-132809RO6836191CS-0204056G18370US9353081, 3-1N-propanamideMolecular Formula C22H25N3O2Molecular Weight363.5InChIInChI=1S/C22H25N3O2/c1-3-21(26)24-19-6-4-5-16-17(12-23-13-18(16)19)14-7-9-20-15(11-14)8-10-22(27)25(20)2/h7,9,11-13,19H,3-6,8,10H2,1-2H3,(H,24,26)/t19-/m1/s1InChI KeyVDEUDSRUMNAXJG-LJQANCHMSA-NIsomeric SMILESCCC(=O)N1CCCC2=C1C=NC=C2C3=CC4=C(C=C3)N(C(=O)CC4)C

Patent InformationPatent IDTitlePublication DateUS2013/79365NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES2013WO2013/41591NEW BICYCLIC DIHYDROQUINOLINE-2-ONE DERIVATIVES2013

Physical Data

AppearanceSolid

Spectra

No data available

Route of Synthesis (ROS)

Route of Synthesis (ROS) of Baxdrostat (CIN-107) CAS 1428652-17-8

ConditionsYieldWith Chiralpak AD In n-heptane; isopropyl alcohol Resolution of racemate;Experimental Procedure2; 3 (-)-(R or S)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide and (+)-(S or R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide(-)-(R or S)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide and (+)-(S or R)-N-(4-(1-Methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamideThe title compounds were prepared by chiral separation of (rac)-N-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide (example 1) on a Chiralpak AD (40% 2-propanol in n-heptane) to give after precipitation from CH2Cl2 with n-pentane 28% of (-)-(R or S)-N-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide (example 2) as off-white powder, MS: 364.2 (M+H+) and 26% of (+)-(S or R)-N-(4-(1-methyl-2-oxo-1,2,3,4-tetrahydroquinolin-6-yl)-5,6,7,8-tetrahydroisoquinolin-8-yl)propionamide (example 3) as off-white powder. MS: 364.2 (M+H+).A 28%B 26%

Safety and Hazards

Pictogram(s)SignalWarningGHS Hazard StatementsH302 (100%): Harmful if swallowed H361d (100%): Suspected of damaging the unborn child H373 (100%): May causes damage to organs through prolonged or repeated exposure Precautionary Statement CodesP203, P260, P264, P270, P280, P301+P317, P318, P319, P330, P405, and P501(The corresponding statement to each P-code can be found at the GHS Classification page.)

Other Data

HS CodeStorageUnder room temperature away from lightShelf Life2 yearsMarket Price

DruglikenessLipinski rules componentMolecular Weight363.459logP2.309HBA5HBD1Matching Lipinski Rules4Veber rules componentPolar Surface Area (PSA)62.3Rotatable Bond (RotB)4Matching Veber Rules2

Use PatternBaxdrostat (CIN-107) is an aldosterone synthase inhibitor (ASI) intended for antihypertensive treatment in refractory hypertension. It directly inhibits the synthesis of aldosterone, contributing to its blood pressure-lowering effects.
https://www.chemwhat.com/baxdrostat-cin-107-cas-1428652-17-8/

Comments

Post a Comment

Popular posts from this blog

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Benzocyclobutene (BCB) is an organic compound with a rigid molecular structure composed of a conjugated benzene ring and a four-membered ring. Its excellent thermal stability and electrical properties have made it a highly promising candidate for next-generation electronic materials. Historically, its industrial adoption has been constrained by high production costs, complex purification processes, and limited output. However, with growing demand in high-end applications and recent advances in upstream technology, BCB is now poised for industrial-scale deployment. Material Properties and Structural Advantages BCB (C₈H₈) is a non-polar molecule, free of ester, carboxyl, or amide groups, giving it excellent dielectric properties and low moisture absorption. Its dielectric constant (Dk) and dissipation factor (Df) remain stable across wide temperature and frequency ranges—key metrics for ensuring signal integrity in high-frequency, high-speed communication systems. Unlike conventional m...
Post a Comment
Read more

The World's Largest Producer of Squaric Acid Emerges: Watson Leads the Way

In a groundbreaking development for the chemical industry, Watson has officially claimed the title of the world’s largest producer of squaric acid. This achievement marks a significant milestone, positioning the company as a global leader in the production of this highly versatile compound, widely valued in pharmaceuticals, polymer research, and advanced materials. What is Squaric Acid? Squaric acid, also known as quadratic acid, is a four-carbon cyclic diketone with two ketone groups and two hydroxyl groups arranged symmetrically. It is renowned for its stability and strong acidity, making it a unique compound in both organic and inorganic chemistry. Its derivatives find applications in creating advanced coatings, conductive polymers, and as intermediates in drug synthesis. Watson: Redefining Excellence in Squaric Acid Production Watson’s rise to the top of the squaric acid industry is backed by its unmatched production capacity, cutting-edge technology, and unwavering commitment...
Post a Comment
Read more

BCB (Benzocyclobutene): — Watson International Enables the Transition from Concept to Scalable Application

Despite BCB’s well-established performance advantages, its commercialization has long been hindered by production cost and scalability challenges. Watson International has made critical breakthroughs in BCB industrialization through integrated innovation in synthesis, purification, and material formulation: Cost Reduction: By optimizing synthetic pathways and improving by-product recovery, Watson has significantly reduced the unit production cost of BCB, enabling cost-effective scaling; High Purity Production: Advanced purification and process control technologies ensure high-purity BCB under mass-production conditions—meeting stringent requirements from high-end electronic manufacturers; Versatile Co-polymerization: Watson’s BCB materials are compatible with other advanced resins such as BMI and PPO, allowing for custom co-polymer design and performance tuning.
Post a Comment
Read more